Cost-effectiveness of interventions to improve hand hygiene in healthcare workers in middle-income hospital settings: a model-based analysis

N. Luangasanatip\textsuperscript{a, b, *}, M. Hongsuwan\textsuperscript{a}, Y. Lubell\textsuperscript{a, c}, D. Limmathurotsakul\textsuperscript{a, d}, P. Srisamang\textsuperscript{e}, N.P.J. Day\textsuperscript{a, c}, N. Graves\textsuperscript{b, f}, B.S. Cooper\textsuperscript{a, c}

\textsuperscript{a} Mahidol—Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand \\
\textsuperscript{b} School of Public Health, Queensland University of Technology, Brisbane, Australia \\
\textsuperscript{c} Centre for Tropical Medicine and Global Health, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK \\
\textsuperscript{d} Department of Tropical Hygiene, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand \\
\textsuperscript{e} Department of Pediatrics, Sanpasithiprasong Hospital, Ubon Ratchatani, Thailand \\
\textsuperscript{f} Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, Australia

\textbf{SUMMARY}

\textbf{Background:} Multi-modal interventions are effective in increasing hand hygiene (HH) compliance among healthcare workers, but it is not known whether such interventions are cost-effective outside high-income countries.

\textbf{Aim:} To evaluate the cost-effectiveness of multi-modal hospital interventions to improve HH compliance in a middle-income country.

\textbf{Methods:} Using a conservative approach, a model was developed to determine whether reductions in meticillin-resistant \textit{Staphylococcus aureus} bloodstream infections (MRSA-BSIs) alone would make HH interventions cost-effective in intensive care units (ICUs). Transmission dynamic and decision analytic models were combined to determine the expected impact of HH interventions on MRSA-BSI incidence and evaluate their cost-effectiveness. A series of sensitivity analyses and hypothetical scenarios making different assumptions about transmissibility were explored to generalize the findings.

\textbf{Findings:} Interventions increasing HH compliance from a 10\% baseline to \textgreek{>}20\% are likely to be cost-effective solely through reduced MRSA-BSI. Increasing compliance from 10\% to 40\% was estimated to cost US$2515 per 10,000 bed-days with 3.8 quality-adjusted life-years (QALYs) gained in a paediatric ICU (PICU) and US$1743 per 10,000 bed-days with 3.7 QALYs gained in an adult ICU. If baseline compliance is not \textgreek{>}20\%, the intervention is always cost-effective even with only a 10\% compliance improvement.

\textbf{Conclusion:} Effective multi-modal HH interventions are likely to be cost-effective due to preventing MRSA-BSI alone in ICU settings in middle-income countries where baseline compliance is typically low. Where compliance is higher, the cost-effectiveness of
Introduction

Hospital-acquired infections (HAIs) are a major cause of morbidity and mortality among hospitalized patients [1]. HAIs are also associated with a substantial economic burden due to longer hospital stays and additional antibiotic costs [2]. The risk of infection in developing countries is two to 20 times higher than in developed countries [3]. In Thailand, among hospitalized patients, the point prevalence of nosocomial infection has been estimated at 6.5% and ~250,000 patients are believed to have an HAI each year [4].

Direct patient contact with healthcare workers (HCWs) transiently contaminated with nosocomial pathogens is believed to be the primary route of transmission. Improving HCW hand hygiene compliance can minimize the impact of this transmission route and reduce the incidence of nosocomial infection [5]. A multi-modal intervention including system change, training and education, observation and feedback, reminders, and a hospital safety climate has been developed and promoted by the World Health Organization (WHO). This campaign (referred to as WHO-5) has been shown to be effective in increasing hand hygiene compliance [5,6]. Hand hygiene promotion is also relatively easy to implement and requires a modest level of investment. Nevertheless, in many healthcare settings, particularly in low- and middle-income countries, compliance remains poor and reports of rates of <10% may be typical [7–9].

Transmission dynamic models are useful tools to help understand the likely impact of interventions to control communicable diseases. Moreover, their use in health-economic evaluations of interventions that reduce transmission is essential to fully capture intervention benefits. However, whereas several studies have used dynamic models to consider hospital infections [10,11], economic evaluations of hand hygiene interventions have used only static models and have largely neglected developing countries where the need for appropriate investment is greatest [12–16]. Whereas one previous cohort study in Vietnam concluded that a hand hygiene intervention was cost-saving (i.e. the reduction in costs from HAIs averted exceeded the intervention cost), there have been no systematic attempts to quantify the levels of investment in hand hygiene promotion under which it remains cost-effective or to explore how appropriate levels of investment depend on pre-intervention levels of hand hygiene compliance [16].

The aims of this study are to develop a dynamic model-based framework for evaluating the cost-effectiveness of hand hygiene promotion interventions and use it to evaluate the cost-effectiveness of such interventions in a middle-income country. Our analysis is informed by data from a typical regional hospital in Thailand, a middle-income country with a gross domestic product (GDP) per capita approximately equal to the world median. We focus on MRSA-BSI as this is one of the most serious and best-studied types of infection in ICU patients, there is clear evidence of frequent patient-to-patient transmission of MRSA, and evidence that such transmission can be interrupted by improved hand hygiene [17–19]. Hand hygiene interventions should also reduce other types of MRSA infections and infections with other organisms. However, since these are harder to quantify, we take a conservative approach by focusing on MRSA-BSI alone and are therefore likely to under-estimate the true health benefits of the intervention [20].

Methods

Overall description

Transmission dynamic and decision analytic models were combined to simulate the transmission dynamics and evaluate the impact and cost-effectiveness of hand hygiene interventions. Two ICU settings were considered: a paediatric intensive care unit (PICU) and an adult intensive care unit (adult ICU). Epidemiological and economic parameters were derived from detailed local data from a typical tertiary hospital in Northeast Thailand. Information about catchment area, staff:patient ratios, and further details about the ICUs have been described elsewhere [21,22]. Incidence of hospital-acquired and healthcare-associated BSI from this and other hospitals in the same region have also been reported in previous studies [22,23].

Transmission dynamic model

A previously described deterministic host–vector model was constructed to simulate MRSA transmission dynamics in an ICU (Figure 1) [24]. Patients can be admitted to the ICU either uncolonized or colonized with MRSA. Uncolonized patients can become colonized or infected by contact with transiently colonized HCWs. HCWs can be decolonized by performing hand
### Table I
Model parameters

| Parameters | Paediatric ICU | Adult ICU | Distribution | Source |
|------------|----------------|-----------|--------------|--------|
|            | Mean  | 2.5<sup>th</sup> percentile | 97.5<sup>th</sup> percentile | Mean  | 2.5<sup>th</sup> percentile | 97.5<sup>th</sup> percentile |                |        |
| Transmission dynamic model | Proportion of admissions colonized with MRSA | 0.063 | 0.029 | 0.108 | 0.087 | 0.038 | 0.139 | Beta | [23] |
| HCW—patient transmission probability per contact | 0.0065 | 0.0028 | 0.0105 | 0.0113 | 0.0061 | 0.0192 | Beta | [23,24] |
| Patient—HCW transmission probability per contact | 0.132 | 0.078 | 0.194 | 0.132 | 0.078 | 0.194 | Beta | [24] |
| Patient/HCW contacts per day (per patient) | 8 | — | — | 8 | — | — | Direct observation | |
| HCW/patient contacts per day (per HCW) | 14 | — | — | 9 | — | — | Direct observation | |
| Infection rate from colonized (per day) | 0.0013 | 0.0007 | 0.0021 | 0.0013 | 0.0008 | 0.0020 | Gamma | Database |
| Probability of attributable death given MRSA-BSI | 0.439 | 0.338 | 0.5390 | 0.439 | 0.338 | 0.539 | Beta | [27] |
| Removal rate of uncolonized patient (1/LOS) (per day) | 0.164 | — | — | 0.173 | — | — | Database | |
| Removal rate of colonized patients (1/LOS) (per day) | 0.164 | — | — | 0.173 | — | — | Database | |
| No. of beds | 7 | — | — | 10 | — | — | Database | |
| No. of HCWs (per shift) | 4 | — | — | 9 | — | — | Database | |
| Hand hygiene compliance (baseline) | 0.1 | — | — | 0.1 | — | — | Database | |
| Economic model | Cost (US$, 2016) | 675.4 | 281.4 | 1069.4 | 719.9 | 305.0 | 1134.6 | Gamma | [28–30] |
| Hand hygiene intervention (per ward per year) | ICU bed day | 47.3 | 15.3 | 71.8 | 47.3 | 15.3 | 71.8 | Gamma | Database, [32] |
| General ward bed day | 5.5 | 2.1 | 10.5 | 5.5 | 2.1 | 10.5 | Gamma | Database, [32] |
| Treatment MRSA-BSI (per case) | 142.8 | 265.4 | 478.6 | 214.2 | 95.6 | 398.1 | Gamma | [33,35,36] |
| Excess length of stay due to MRSA-BSI (per case) | 2.2 | —0.1 | 4.6 | 1.4 | —1.3 | 4.1 | Normal | Database |
| Utility post-ICU | 0.72 | 0.56 | 0.88 | 0.72 | 0.56 | 0.88 | Beta | [36–39] |
| QALYs gained per death averted (3% discounted) | 17.95 | 10.48 | 24.67 | 10.31 | 7.92 | 12.76 | Gamma | Database, [21] |

ICU, intensive care unit; MRSA, meticillin-resistant <i>Staphylococcus aureus</i>; HCW, healthcare worker; BSI, bloodstream infection; LOS, length of hospital stay; QALY, quality-adjusted life-year.
hygiene. Colonized patients have a specified risk of developing MRSA-BSI. The model outputs the number of newly colonized patients, the number of MRSA-BSIs and the number of deaths over one year under different levels of hand hygiene compliance. The model was implemented in R, using the package 'deSolve' to numerically solve the equations [25,26]. Model outcomes were fed into the decision analytic model. Full technical details are given in Appendix A.

Model parameters were obtained from various sources (Table I). MRSA carriage data were derived from a previous observational study in North-east Thailand [22,27]. Estimates of the per-contact transmission probabilities (HCW to patient and patient to HCW) were derived using these data, combined with previous estimates of the probability of transmission of a colonized patient to HCW (see Appendix A) [27,40]. The rates at which colonized patients acquired an MRSA-BSI were estimated from the average number of cases per year at each ward divided by the expected number of colonized bed-days (estimated from the carriage data). Risk of death due to MRSA-BSI was taken from an observation study in the same setting [22]. The number of beds, number of HCWs per shift, rates of ICU discharge, ward-specific contact rates, and the baseline hand hygiene compliance were directly observed from the same hospital.

Economic evaluation

Cost-utility analysis was performed from a healthcare provider’s perspective. The cost of the hand hygiene intervention was estimated over a period of one year. Health benefits were measured with a lifetime horizon and a 3% discounting rate. Costs were adjusted to 2016 values with the exchange rate of 1 US$ = 33 Thai Baht [41]. This economic evaluation is in accordance with the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement [42].

| HHC | MRSA-BSI avoided per 10,000 bed-days | Deaths averted | Incremental cost (US$) | QALYs gained | ICER | Average monetary net benefits (95% CI) (US$) | Average IMNB (95% CI) (US$) |
|-----|--------------------------------------|----------------|------------------------|--------------|------|---------------------------------------------|-----------------------------|
|     |                                       |                |                        |              |      |                                             |                             |
| Paediatric ICU |                                       |                |                        |              |      |                                             |                             |
| Baseline (HHC 10%) |                                       |                |                        |              |      | 30,355,764 19,974,308 43,152,328 | – – – |
| HHC 20% | 0.093 | 0.1593 | 653.34 | 0.69 | 951.00 | 30,358,438 19,983,010 43,153,618 | 2674 153 7694 |
| HHC 40% | 0.1318 | 0.2258 | 644.05 | 0.97 | 660.84 | 30,359,838 19,986,042 43,154,482 | 4074 555 11,054 |
| HHC 60% | 0.143 | 0.2453 | 641.32 | 1.06 | 605.59 | 30,360,250 19,986,829 43,154,760 | 4107 680 12,024 |
| HHC 40% vs HHC 60% | 0.011 | 0.0196 | 672.81 | 0.08 | 7959.42 | 30,360,250 19,986,829 43,154,760 | (263) (818) 411 |
| Adult ICU |                                       |                |                        |              |      |                                             |                             |
| Baseline (HHC 10%) |                                       |                |                        |              |      | 21,563,698 16,822,741 26,943,092 | – – – |
| HHC 20% | 0.2326 | 0.2796 | 660.46 | 0.96 | 684.77 | 21,568,718 18,828,312 26,945,105 | 4020 926 9213 |
| HHC 40% | 0.3243 | 0.3898 | 636.25 | 1.35 | 470.60 | 21,569,819 18,829,969 26,946,027 | 5921 1622 13,187 |
| HHC 60% | 0.3503 | 0.4211 | 629.30 | 1.46 | 430.14 | 21,570,164 16,830,431 26,946,285 | 6466 1822 14,288 |
| HHC 40% vs HHC 60% | 0.0260 | 0.0313 | 713.93 | 0.11 | 6431.80 | 21,570,164 16,830,431 26,946,285 | (176) (772) 536 |

ICU, intensive care unit; HHC, hand hygiene compliance; MRSA-BSI, meticillin-resistant Staphylococcus aureus bloodstream infection; QALY, quality-adjusted life year; ICER, incremental cost-effectiveness ratio; IMNB, incremental monetary net benefit.

a Per ward per year.

b Monetary net benefits reported per ward (total admission) assuming a willingness to pay for a QALY of US$4840 (160,000 Thai baht, exchange rate; US$1 = 33 Thai baht).
to pay (WTP) for an unoccupied bed-day [45]. This opportunity cost is typically much lower than the cost calculated with an accounting approach (hospital budget divided by the total patient bed-days) [32]. In the absence of WTP per ICU bed-day in Thailand, the accounting cost was estimated using local hospital financial data and this was multiplied by the ratio of bed-day costs estimated with WTP and accounting approaches reported in a previous study [32].

Treatment for MRSA-BSI was assumed to require a 14-day course of vancomycin with dose regimens following treatment guidelines for hospital-acquired MRSA-BSI. Drug costs were obtained from the Drug Medical Supply Information Center [33].

Estimates of life expectancy among post-ICU patients were taken from a previous study in North-east Thailand [21]. Health-related quality of life among patients after ICU discharge who had MRSA-BSI during the ICU stay was assumed to be the same as general post-ICU patients. These utility values were taken from the literature [36–39]. The median utility of 0.72 was used in the base case with a range from 0.56 to 0.88 and assumed to be constant.

Analyses

Four scenarios with different baseline versus post-intervention hand hygiene compliance values were considered: (a) 10% vs 20%; (b) 10% vs 40%; (c) 10% vs 60%; and (d) 40% vs 60%. These are consistent with results from a systematic review where odds ratios were estimated to be 6.5 and 11.8 for WHO-5 and WHO-5 plus other interventions among studies using an interrupted time-series design (with a baseline compliance of 10%, these would give post-intervention compliance values of 42% and 57%, respectively) [46].

In each comparison, point estimates of incremental costs ($\Delta C$) and QALYs gained ($\Delta Q$) due to the intervention and the incremental cost-effectiveness ratio (ICER; $\Delta C/\Delta Q$) were calculated. The threshold willingness to pay per QALY gained ($\lambda$) was taken as GDP per capita (US$4848), and a threshold value of three times GDP per capita was considered in a scenario analysis [47]. The latter threshold corresponds to WHO criteria for a cost-effective intervention and the former to a highly cost-effective intervention [34]. Interventions with ICERs below

Figure 2. Base case and scenario analyses plotting probability density of incremental net monetary benefits for hand hygiene intervention across four different hand hygiene compliance (HHC) scenarios (baseline compliance at 10% compared with post intervention at 20%, 40% and 60% and baseline compliance at 40% compared with post intervention at 60%) at willingness to pay per quality-adjusted life-year gained of US$4848 for paediatric intensive care unit (A) and adult intensive care unit (B).
the chosen WTP threshold are, by definition, cost-effective. Probabilistic sensitivity analyses (PSA) were undertaken using 10,000 Monte Carlo iterations where parameters were sampled from specified distributions (Table II). Simulation results were used to calculate the monetary net benefit (MNB), which is defined as $\lambda^*Q - C$ for each level of achieved hand hygiene compliance and the distribution of incremental monetary net benefits (IMNB) for each comparison ($\lambda^*\Delta Q - \Delta C$). In addition, the maximum level of investment in the intervention at which it would still be cost-effective was calculated as monetary incremental benefits ($\lambda^*\Delta Q$) plus the saving in treatment costs from averted infections.

A series of hypothetical scenarios with different assumptions about the transmissibility and prevalence of MRSA colonization at admission were considered. The ward reproduction number ($R_w$), the expected number of MRSA cross-transmissions resulting from a single colonized patient during a single ward stay, assuming all other patients on the ward are susceptible, was varied between 0.5 and 5, while prevalence of MRSA stay, assuming all other patients on the ward are susceptible, resulting from a single colonized patient during a single ward stay, was varied between 1% and 15%.

Changes in costs and health outcomes under different baseline compliance and improvement levels were calculated and combined to evaluate the cost-effectiveness of such interventions in terms of the IMNB. The maximum level of investment at which the intervention would still be cost-effective, the prevalence reduction, and final prevalence in all scenarios were also determined.

Results

Under base case assumptions (with a pre-intervention hand hygiene compliance of 10%), a multi-modal hand intervention (WHO-5) is highly likely to be cost-effective in both PICU and adult ICU settings if it increases hand hygiene compliance to ≥20% (Table II and Appendix B). Conversely, if baseline compliance is 40%, the expected IMNB is likely to be negative, indicating that the intervention is unlikely to be cost-effective solely as a result of reducing MRSA-BSIs (Figure 2).

Risk of death due to MRSA-BSI in our study hospital was estimated to be between two- and three-fold higher than in

| Scenario analysis for base case (baseline hand hygiene compliance of 10% vs 40% hand hygiene compliance) |
| Setting | Incremental outcomes | ICER | Mean IMNB<sup>a,b</sup> (95% CI) (US$) | Mean (95% CI) maximum investment<sup>a,b</sup> (US$) |
| --- | --- | --- | --- | --- |
| **Paediatric ICU, per ward, per year (2016)** | **Costs (US$)** | **QALYs**<sup>c</sup> | **ICER** | **Mean IMNB<sup>a,b</sup> (95% CI) (US$)** | **Mean (95% CI) maximum investment<sup>a,b</sup> (US$)** |
| Base case | 644 | 0.97 | 661 | 4074 (555—11,054) | 4839 (1344—11,668) |
| Cost of hand hygiene intervention (5-fold increase from US$675 to US$3375) | 3369 | 0.97 | 3457 | 1453 (−2919—9586) | 4833 (1320—12,306) |
| QALY gained per death averted amongst post-ICU patients (lower bound = 10.48 instead of 17.95) | 644 | 0.58 | 1113 | 2156 (32—6262) | 2836 (776—6880) |
| No utility weights (LE = 24.93 instead of 17.95) | 644 | 1.36 | 474 | 5953 (1127—15,458) | 6634 (1814—16,069) |
| Low attributable mortality due to MRSA-BSI (at 20%) | 644 | 0.45 | 1422 | 1533 (−156—4850) | 2213 (588—5488) |
| High attributable mortality due to MRSA-BSI (at 50%) | 644 | 1.13 | 571 | 4815 (840—12,742) | 5498 (1547—13,345) |
| Include additional stay in general wards given BSI (12.8 days) | 636 | 0.97 | 652 | 4161 (642—11,118) | 4837 (1350—11,725) |
| **Adult ICU, per ward, per year (2016)** | **Costs (US$)** | **QALYs**<sup>c</sup> | **ICER** | **Mean IMNB<sup>a,b</sup> (95% CI) (US$)** | **Mean (95% CI) maximum investment<sup>a,b</sup> (US$)** |
| Base case | 636 | 1.35 | 471 | 4020 (926—9213) | 5513 (1560—13,224) |
| Cost of intervention (5-fold increase from US$720 to US$3600) | 3535 | 1.35 | 2623 | 3102 (−1722—10,312) | 6723 (2498—13,735) |
| QALY gained per death averted amongst post-ICU patients (lower bound = 7.92 instead of 10.31) | 636 | 1.05 | 606 | 4460 (1178—9822) | 5184 (1927—10,572) |
| No utility weights (LE = 14.32 instead of 10.31) | 636 | 1.90 | 335 | 8580 (2709—18,321) | 9304 (3455—19,002) |
| Low attributable mortality due to MRSA-BSI (at 20%) | 636 | 0.89 | 712 | 3696 (788—8661) | 4421 (1542—9432) |
| High attributable mortality due to MRSA-BSI (at 50%) | 636 | 1.56 | 409 | 6905 (2132—14,717) | 7632 (2884—15,403) |
| Include additional stay in general wards given BSI (12.8 days) | 620 | 1.35 | 460 | 6017 (1743—12,935) | 6743 (2518—13,648) |

<sup>a</sup> QALY, quality-adjusted life year; ICER, incremental cost-effectiveness ratio; IMNB, incremental monetary net benefit; CI, confidence interval; ICU, intensive care unit; LE, life expectancy; MRSA-BSI, methicillin-resistant Staphylococcus aureus bloodstream infection; HHC, hand hygiene compliance.

<sup>b</sup> Incremental monetary net benefits and maximum investment at which the intervention would still be cost-effective assuming a willingness to pay for a QALY of US$4,840 (160,000) exchange rate; SUS 1 = 33 Thai baht.
high-income countries [22,35]. However, a scenario analysis showed that the intervention is still highly cost-effective if a lower mortality risk estimated from high-income settings is used instead (Table III). When the WTP threshold was three times GDP per capita (US$14,545), under base case assumptions (with a pre-intervention hand hygiene compliance of 10% and post-intervention compliance of 40%), the IMNBs were positive for both PICU and adult ICU.

In hypothetical scenario analyses, the hand hygiene intervention was found to be cost-effective in most scenarios, especially when there was high transmissibility and a high prevalence of MRSA colonization on admission (Figure 3). In the situations where the transmissibility is low ($R_0 = 0.5$), where prevalence of MRSA colonization at admission is 5%, and where baseline compliance is <20% in both the PICU and the adult ICU, the intervention is always cost-effective even with only a 10% compliance improvement using the cost estimates in Table I. When the baseline compliance is ≤20%, the intervention will always be cost-effective if the intervention cost per year is less than US$1557 in the PICU and US$888 in the adult ICU, provided that the intervention increases compliance by ≥10%. Prevalence reduction of MRSA carriage and the final prevalence of all hypothetical scenarios are shown in Figure 4.

Discussion

Hand hygiene promotion using the WHO multi-modal campaign is likely to be highly cost-effective for ICU settings in Thailand where baseline compliance is low (<20%) solely as a result of preventing MRSA-BSI. Factors that tended to make the intervention more cost-effective were low baseline compliance, high prevalence of colonization at admission, and high rates of transmission. With higher baseline compliance, the intervention may often still be highly cost-effective as a result of reduced MRSA-BSI alone if rates of MRSA carriage on ICU admission or ICU transmission are sufficiently high.

Because we ignored impacts of the intervention on other types of HAI (other MRSA infections and infections with other pathogens) our analysis is conservative and likely to underestimate health benefits. MRSA-BSIs represent only 5.1% of hospital-acquired BSIs in North-east Thailand, whereas Gram-negatives account for 67.6% [23]. Evidence linking increased hygiene with reduced infection rates is less compelling for Gram-negative organisms than it is for MRSA, but there are credible reports that such an association exists [48,49]. Some of the strongest evidence concerns multidrug-resistant Acinetobacter spp., where a segmented regression analysis found that a hand hygiene intervention was associated with a substantial change in incidence of infections with extensively drug-resistant Acinetobacter spp. in Taiwan [13]. Acinetobacter spp. has also been reported to be a frequent contaminant of the hands of HCWs in endemic settings in South-east Asia, strengthening the evidence for a causal link between increased hand hygiene and reduced infections [50]. Since Acinetobacter spp. are the largest single cause of hospital-acquired BSI in North-east Thailand, if infections with these organisms can be reduced substantially by improved hand hygiene, the implications for our analysis could be substantial [22]. Whereas our work provides an analytical framework for such an evaluation, better data on the epidemiology of Acinetobacter spp. and the effects of hand hygiene are needed to inform it.

To the best of our knowledge, our study is the first economic evaluation of a hand hygiene intervention to make use of a dynamic model in a developing country [12–16]. In previous economic evaluations in high-income countries, Pittet et al. (in Switzerland), and Chen et al. (in Taiwan) used data from observational studies to estimate reductions in infections due to hand hygiene interventions. Pittet et al. concluded that if only 1% of the observed reduction was due to the intervention it would have been cost-saving. Chen et al. also concluded that their intervention was likely to be cost-saving. Huis et al. (in the Netherlands) used trial data to inform a cost-effectiveness analysis, assuming a linear relationship between hand hygiene compliance and reduced infections, concluding that the intervention was likely to be cost-effective if the willingness to pay for a 1% reduction in the HAI rate was about US$6000. A study in the UK also concluded that hand hygiene interventions were likely to be cost-saving even if the reduction in rates of HAI were as low as 0.1%. As in our study, this report explicitly calculated QALY gains. However, unlike the other studies, staff time was not accounted for when costing the intervention. A previous study in a middle-income country (Vietnam) concluded that a hospital-wide hand hygiene promotion was cost-saving [16].

Direct comparison of these findings with ours is difficult for three reasons. First, only one of the previous studies quantified benefits in terms of final health outcomes (QALYs) [12]. Second, bed-day costs are much greater in high-income settings and account for most of the costs associated with HAI. In developing country settings, costs of antibiotics to treat infections are likely to be the dominant cost [16]. Third, there are important differences in aims and methodology. We focused on MRSA-BSI (where we have strong evidence that it can be reduced by hand hygiene), reasoning that if the intervention is cost-effective for this outcome alone then it should certainly be cost-effective overall. We also made use of important methodological advances, accounting for the expected non-linear association between hand hygiene compliance and infection rates using a mathematical model, avoiding time-dependent biases when estimating increased length of stay, valuing bed-days based on opportunity cost rather than using an accounting approach, and estimating life-years gained by preventing mortality using data from a large linked-database study [10,21,24,43,32]. These advances, combined with the much lower bed-day costs, help explain why we estimated the cost per infection to be a few hundred dollars, whereas studies in other countries in both high- and middle-income countries estimated it to be a few thousand [13–16].

Our study has some limitations, the most important of which is that data are not yet available that allow us to include other pathogens in the model. In addition, since local information on the resources used for the hand hygiene intervention is limited, we were dependent on estimates of resource used for hand hygiene interventions from studies outside Thailand. A further limitation is that we evaluated the intervention over only a one-year post-intervention period where the initial investment would be most. Additional costs to maintain the compliance in the later years are difficult to quantify but likely to be less costly than the first year.

In conclusion, effective multi-modal hand hygiene interventions are likely to be cost-effective in ICU settings in...
Figure 3. Incremental monetary net benefit (IMNB) (top); blue for IMNB > 0 (cost-effective) and red for IMNB < 0 (not cost-effective) and maximum intervention cost at which the intervention would still be cost-effective (bottom) from hypothetical scenario analyses with different values of baseline hand hygiene compliance, compliance improvement, and the ward reproduction number ($R_A$) for paediatric intensive care unit (PICU) (left) and adult ICU (right) at willingness to pay per quality-adjusted life-year gained of US$4848. Proportion of admissions colonized with meticillin-resistant *Staphylococcus aureus*: (A) 0.01, (B) 0.05, (C) 0.10, (D) 0.15.
Figure 4. Prevalence reduction of meticillin-resistant Staphylococcus aureus (MRSA) carriage due to intervention (top) and equilibrium prevalence of MRSA carriage after improved hand hygiene compliance (bottom) from hypothetical scenario analyses with different values between baseline hand hygiene compliance, compliance improvement and the ward reproduction number (RA) for paediatric intensive care unit (PICU) (left) and adult ICU (right). Proportion of admissions colonized with meticillin-resistant Staphylococcus aureus: (A) 0.01, (B) 0.05, (C) 0.10, (D) 0.15.
typical middle-income countries due to reduced incidence of MRSA-BSI alone under a wide range of circumstances. When this is not so, the cost-effectiveness of interventions to further improve hand hygiene will depend on the impact on other infections and other pathogens. Further work is needed to quantify this.

Acknowledgements

We are grateful to all authors of the literature included in this article for supporting material and helpful information. We also would like to thank the infection control staff of Sanpathiprasong Hospital for technical support.

Conflict of interest statement
None declared.

Funding source
This research was part of the Wellcome Trust–Mahidol University—Oxford Tropical Medicine Research Programme supported by the Wellcome Trust of Great Britain (089275/Z/09/Z). B. Cooper was supported by The Oak Foundation and The Medical Research Council and Department for International Development (grant number MR/K006924/1).

Appendix A. Supplementary data

Supplementary data related to this article can be found at https://doi.org/10.1016/j.jhin.2018.05.007

References

[1] Ponce-de-Leon S. The needs of developing countries and the resources required. J Hosp Infect 1991;18:376–81.
[2] Graves N, Weinholt D, Tong E, Birkett F, Doidge S, Ramritu P, et al. Effect of healthcare-acquired infection on length of hospital stay and cost. Infect Control Hosp Epidemiol 2007;28:280–92.
[3] Allegranzi B, Bagheri N, Combesure C. Burden of endemic healthcare-associated infection in developing countries: systematic review and meta-analysis. Lancet 2011;377:228–41.
[4] Ochsner KJ, Katholi CR, James AH, Kashima H, Truitt ME, et al. Development of a global database of antimicrobial resistance. Clin Infect Dis 2011;52(Suppl 1):S4–15.
[5] World Health Organization. Guidelines on hand hygiene in health care (first global patient safety challenge — clean care is safer care). Geneva: WHO; 2009.
[6] Gould DJ, Moralejo D, Dery N, Chudleigh JH, Taljaard M. Interventions to improve hand hygiene compliance in patient care (second update). Cochrane Database Syst Rev 2017;9:CD005186.
[7] Allegranzi B, Sax H, Bengaly N, Richet H, Mintz DN, Chraiti MN, et al. Successful implementation of the World Health Organization hand hygiene improvement strategy in a referral hospital in Mali, Africa. Infect Control Hosp Epidemiol 2010;31:133–41.
[8] Apsanaranthanar A, Thongphubeth K, Yuekeny C, Warren DK, Fraser VJ. Effectiveness of a catheter-associated bloodstream infection bundle in a Thai tertiary care center: a 3-year study. Am J Infect Control 2010;38:449–55.
[9] Picheansathan W, Peason A, Suchaxaya P. The effectiveness of a promotion programme on hand hygiene compliance and nosocomial infections in a neonatal intensive care unit. Int J Nurs Pract 2008;14:315–21.
[10] Jit M, Brisson M. Modelling the epidemiology of infectious diseases for decision analysis: a primer. Pharmacoeconomics 2011;29:371–86.
[11] van Kleef E, Robotham J, M. Jit, Deeny SR, Edmunds WJ. Modelling the transmission of healthcare associated infections: a systematic review. BMC Infect Dis 2013;13:28:294.
[12] National Patient Safety Agency. The economic case. Implementing near-patient alcohol handrub in your trust. NHS; 2004. Available at: www.npsa.nhs.uk/EasySiteWeb/GatewayLink.aspx?aid=5925 [last accessed May 2018].
[13] Chen YC, Sheng WH, Wang JT, Chang SC, Lin HC, Tien KL, et al. Effectiveness and limitations of hand hygiene promotion on decreasing healthcare-associated infections. PLoS One 2011;6:e27163.
[14] Huis A, Hulscher M, Adang E, Grol R, van Achterberg T, Schoonhoven L. Cost-effectiveness of a team and leaders directed strategy to improve nurses’ adherence to hand hygiene guidelines: a cluster randomised trial. Int J Nurs Stud 2013;50:518–26.
[15] Pittet D, Sax H, Hugonnet S, Harbarth S. Cost implications of successful hand hygiene promotion. Infect Control Hosp Epidemiol 2004;25:264–6.
[16] Thi Anh Thu L, Thi Hong Thoa V, Thi Van Trang N, Thu Van D, Thi Kim Anh L, et al. Cost-effectiveness of a hand hygiene program on health-care-associated infections in intensive care patients at a tertiary care hospital in Vietnam. Am J Infect Control 2015;43:e93–9.
[17] Barnett AG, Page K, Campbell M, Brain D, Martin E, Rashleigh-Rolls R, et al. Changes in healthcare-associated Staphylococcus aureus bloodstream infections after the introduction of a national hand hygiene initiative. Infect Control Hosp Epidemiol 2014;35:1029–36.
[18] Stone SP, Fuller C, Savage J, Cookson B, Hayward A, Cooper B, et al. Evaluation of the national Cleanyourhands campaign to reduce Staphylococcus aureus bacteraemia and Clostridium difficile infection in hospitals in England and Wales by improved hand hygiene: four year, prospective, ecological, interrupted time series study. BMJ 2012;3:e3005.
[19] van Kleef E, Luangasanatip N, Bonten MJ, Cooper BS. Why sensitive bacteria are resistant to hospital infection control. Wellcome Open Res 2017;2:16.
[20] Graves N, Page K, Marten E, Brain D, Hall L, Campbell M, et al. Cost-effectiveness of a national initiative to improve hand hygiene compliance using the outcome of healthcare associated Staphylococcus aureus bacteraemia. PLoS One 2016;11:e0148190.
[21] Luangasanatip N, Hongsuwan M, Lubell Y, Limmathurosakul D, Teparrukkul P, Chaowarat S, et al. Long-term survival after Acinetobacter bacteraemia in intensive care unit discharge in Thailand: a retrospective study. Crit Care 2013;17:R219.
[22] Nickerson EK, Hongsuwan M, Limmathurosakul D, Wuthiekanun V, Shah KR, Srisomang P, et al. Staphylococcus aureus bacteraemia in a tropical setting: patient outcome and impact of antibiotic resistance. PLoS One 2009;4:e4308.
[23] Hongsuwan M, Srisomang P, Kanoksil M, Luangasanatip N, Jatapat A, Day NP, et al. Increasing incidence of hospital-acquired and healthcare-associated bacteraemia in northeast Thailand: a multicenter surveillance study. PLoS One 2014;9:e109324.
[24] McBryde ES, Pettitt AN, McElwain DL. A stochastic mathematical model of meticillin resistant Staphylococcus aureus transmission in an intensive care unit: predicting the impact of interventions. J Theor Biol 2007;245:470–81.
[25] Soetaert K, Petzoldt T, Setzer RW. Solving differential equations in R: Package deSolve. J Statist Software 2010;33:1–25.
[26] R Core Team. R: a language and environment for statistical, computing. Vienna: R Foundation for Statistical Computing; 2014. Available at: http://www.R-project.org/ [last accessed January 2015].
[27] Worby C. Statistical inference and modelling for nosocomial infections and the incorporation of whole genome sequence data [PhD thesis]. UK: University of Nottingham; 2012.
[28] Page K, Barnett AG, Campbell M, Brain D, Martin E, Fulop N, et al. Costing the Australian national hand hygiene initiative. J Hosp Infect 2014;88:141–8.

[29] Ministry of Public Health, Thailand. Healthcare professional pay scale under committee of human resources. 2013.

[30] Grayson ML, Javie LJ, Martin R, Johnson PD, Jodoin ME, Bureau of Trade and Economic indices, Ministry of Commerce, Thailand: report for consumer price index of Thailand 2014. Available at: http://www.indexpr.moc.go.th/price_present/cpi/stat/others/indexrg_report2.asp?list_year=2553 [last accessed January 2015].

[31] Sacanella E, Pérez-Castejón JM, Nicolás JM, Masanes F, Navarro M, Castro P, et al. Functional status and quality of life 12 months after discharge from a medical ICU in healthy elderly patients: a prospective observational study. Crit Care 2011;15:R105.